| Literature DB >> 33562748 |
Jimin Xu1, Judith Berastegui-Cabrera2, Marta Carretero-Ledesma2, Haiying Chen1, Yu Xue1, Eric A Wold1, Jerónimo Pachón2,3, Jia Zhou1, Javier Sánchez-Céspedes2.
Abstract
Human adenoviruses (HAdVs) display a wide range of tissue tropism and can cause an array of symptoms from mild respiratory illnesses to disseminated and life-threatening infections in immunocompromised individuals. However, no antiviral drug has been approved specifically for the treatment of HAdV infections. Herein, we report our continued efforts to optimize salicylamide derivatives and discover compound 16 (JMX0493) as a potent inhibitor of HAdV infection. Compound 16 displays submicromolar IC50 values, a higher selectivity index (SI > 100) and 2.5-fold virus yield reduction compared to our hit compound niclosamide. Moreover, unlike niclosamide, our mechanistic studies suggest that the antiviral activity of compound 16 against HAdV is achieved through the inhibition of viral particle escape from the endosome, which bars subsequent uncoating and the presentation of lytic protein VI.Entities:
Keywords: adenovirus; antiviral agent; entry inhibition; salicylamide derivatives
Year: 2021 PMID: 33562748 PMCID: PMC7915867 DOI: 10.3390/ijms22041617
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923